Product Pathways - Neuroscience
LRRK2 Antibody #2567
PhosphoSitePlus® protein, site, and accession data: LRRK2
| Applications | Reactivity | Sensitivity | MW (kDa) | Source |
|---|---|---|---|---|
| W | H | Transfected Only | 290 | Rabbit |
Applications Key:
W=Western Blotting
Reactivity Key:
H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Protocols
- 2567:
- Western Blotting
Specificity / Sensitivity
The LRRK2 Antibody is recommended for transfected total LRRK2 only. The LRRK2 antibody detects a background band in extracts of wild-type and LRRK2 knock-out mouse brain at ~290kD.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide surrounding Gly2090 of human LRRK2. Antibodies are purified by protein A and peptide affinity chromatography.
Western Blotting
Western blot analysis of extracts from HEK-293 cells, transfected with GFP alone (lane 1) or GFP-LRRK2 (lane 2), using LRRK2 Antibody.
Background
Parkinson’s disease (PD), the second most common neurodegenerative disease after Alzheimer’s, is a progressive movement disorder characterized by rigidity, tremors, and postural instability. The pathological hallmark of PD is progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies (protein aggregates of α-synuclein, ubiquitin, and other components) in surviving neurons of the brain stem (1). Various genes and loci (α-synuclein/PARK1 and 4, parkin/PARK2, UCH-L1/PARK5, PINK1/PARK6, DJ-1/PARK7, LRRK2/PARK8, synphilin-1, and NR4A2) are genetically linked to PD (2).Leucine-rich repeat kinase 2 (LRRK2) contains amino-terminal leucine-rich repeats (LRR), a Ras-like small GTP binding protein-like (ROC) domain, an MLK protein kinase domain, and a carboxy-terminal WD40 repeat domain. At least 20 LRRK2 mutations have been linked to PD-the G2019S mutation being the most prevalent (3). The G2019S mutation causes increased LRRK2 kinase activity, which induces a progressive reduction in neurite length, leading to progressive neurite loss and decreased neuronal survival (4). The MLK inhibitor CEP-1347 is being tested in PD clinical trials, indicating the potential value of LRRK2 as a therapeutic target for treatment of PD (5).
- Fahn, S. (2003) Ann. NY Acad. Sci. 991, 1-14.
- Moore, D.J. et al. (2005) Annu. Rev. Neurosci. 28, 57-87.
- Mata, I.F. et al. (2006) Trends Neurosci. 29, 286-293.
- MacLeod, D. et al. (2006) Neuron 52, 587-593.
- Parkinson Study Group. (2004) Neurology 62, 330-332.
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
- 2628 α-Synuclein Antibody (IF Preferred)
- 2642 α-Synuclein Antibody
- 2647 α-Synuclein (Syn204) Mouse mAb
- 2644 α/β-Synuclein (Syn205) Mouse mAb
- 2306 DARPP-32 (19A3) Rabbit mAb
- 4211 Parkin (Prk8) Mouse mAb
- 2132 Parkin Antibody
- 2134 DJ-1 Antibody
- 2791 Phospho-Tyrosine Hydroxylase (Ser40) Antibody
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
